Novo Nordisk's Clinical Ledger: Retatrutide's Head-to-Head Win, a Pediatric Insulin Approval and the 4 November Reckoning
Published on 10/31/2026 at 21:01 | Editorial boerse-global.de
Eli Lilly's Wednesday release of Phase 3 data for retatrutide has handed Novo Nordisk a direct clinical challenge in type-2 diabetes — one that a 2.7% share price gain on Friday does nothing to erase. The TRANSCEND-T2D-2 trial pitted Lilly's investigational candidate against Ozempic at a 2 mg dose in adults with type-2 diabetes, and the results favored the challenger on both of the study's headline measures.
After 80 weeks, patients on retatrutide recorded average weight loss of 20.9%, against 9.4% in the Ozempic arm. On glycaemic control, Lilly reported an A1C reduction of 2.2% with retatrutide versus 1.8% with Ozempic. What makes the comparison sting for Novo Nordisk is its architecture: the trial benchmarks a rival's pipeline asset squarely against one of the Danish company's own flagship products. Lilly's figures remain top-line Phase 3 data, not a regulatory verdict on retatrutide.
Reuters reported a negative share price reaction for Novo Nordisk in Copenhagen on Wednesday following publication of the results. Friday's rebound therefore cannot be read as any rebuttal of the study findings — market moves and clinical competitiveness are separate ledgers. The Friday advance also landed in a friendlier sector mood after Eli Lilly's own quarterly numbers, though no direct link between that report and Novo's move has been established. Reuters reported on Thursday that demand for Lilly's injectable weight-loss drugs remains strong and that the company is widening its lead over Novo Nordisk in the GLP-1 market — a signal that cuts both ways, underscoring the competitive pressure even as it lifts the whole sector.
A crowded November calendar
Novo Nordisk's response is a wall of its own science. On Thursday the company announced 26 contributions on its obesity portfolio for ObesityWeek, running 14–17 November in Washington, covering data on CagriSema and Wegovy. A day earlier it had flagged twelve contributions on semaglutide and the experimental agent efruxifermin for The Liver Meeting, scheduled for 5–9 November in Denver.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The most immediate test, however, arrives before either congress. On 4 November Novo Nordisk publishes results for the first nine months of 2026 — the number that will document how the business is actually travelling. That print carries more weight for how the stock is read than any single upbeat session, particularly with Lilly's momentum setting a demanding comparative bar. Strong demand for obesity drugs across the market does not by itself answer how Novo Nordisk is faring against its rival; only the accounts can.
Clinical wins, with caveats attached
Recent pipeline news offers genuine positives, though the details matter. On 20 October the company reported results from a post-hoc analysis of the REDEFINE 1 study showing CagriSema was associated with average weight loss of 25% in women, presented at the annual meeting of the Menopause Society. Because it is a retrospective look at existing trial data, the finding should not be conflated with a standalone new approval decision.
An actual approval came on 23 October, when the FDA cleared Awiqli as the first once-weekly basal insulin for children aged ten and older with type-2 diabetes, according to the company.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Two distinct yardsticks now sit ahead: the financial trajectory, then the scientific evidence. Medical progress strengthens the product story; whether that translates into commercial gains is a question only the 4 November figures — and the data presented in Denver and Washington — can begin to settle.
Ad
Novo Nordisk Stock: New Analysis - 31 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
